View Older Stories View More Recent Stories
-
Roth Capital Assumes Sucampo Pharmaceuticals (SCMP) at Buy
-
Notable Analyst Rating Changes 10/28: (TWTR) (AAPL) (MAS) Upgraded; (FIVE) (MRVL) (SBLK) Downgraded
-
Roth Capital Raises Price Target to $237 on Ultimate Software Group (ULTI) Following 3Q
-
Pre-Open Stock Movers 10/28: (CMI) (HOT) (CAB) (AIG) (AAPL) Higher; (MCUR) (AKAM) (ICPT) Lower (more...)
-
Roth Capital Expects Foreign Currency Exchange Rates to Negatively Hit SodaStream's (SODA) 3Q Results
-
Roth Capital Starts Yelp (YELP) at Sell
-
Roth Capital Starts MeetMe (MEET) at Buy
-
China Yida Holding (CNYD) Forms Special Committee to Evaluate Takeover Offer
-
Roth Capital Maintains Cytokinetics (CYTJK) at 'Buy' Amid Encouraging COSMIC-HF Data
-
Adesto Technologies (IOTS) IPO Opens Higher
-
Adesto Technologies (IOTS) Prices 5M Common Stock IPO at $5/Share
-
Harris & Harris Group Portfolio Company Adesto Raises $25 Million in Initial Public Offering
-
Adesto Technologies Corporation Prices Initial Public Offering
-
Adesto Technologies Corporation Prices Initial Public Offering
-
SolarCity (SCTY) to Report 3Q Earnings on 10/29; Roth Capital Cuts Price Target to $70
-
Spark Therapeutics to Participate in Four Conferences in October and November
-
Ligand Pharma (LGND) Announces FDA CRL for Evomela's NDA; Roth Capital Reiterates Buy
-
NovaBay Pharma (NBY) Prices 12.3M Common Stock, Warrants Offering
-
NovaBay Announces Pricing of Public Offering of Common Stock and Warrants
-
Roth Capital Trims PT on Ligand (LGND) to $138; Will Remove Evomela from Revenue Projections (SPPI)
-
NovaBay Pharma (NBY) Announces Common Stock, Warrants Offering
-
NovaBay Announces Proposed Public Offering of Common Stock and Warrants
-
Roth Capital Raises Price Target Following Natus Medical's (BABY) 3Q Results
-
Strongbridge Biopharma plc Announces Closing of Initial U.S. Public Offering
-
Roth Capital Downgrades Synta Pharma. (SNTA) to Neutral; $1 PT
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces the Closing of its Public Offering of Common Stock
-
bluebird bio (BLUE) Stock Reaction Has No Correlation with Current Data/Program, Roth Capital Says
-
Roth Capital Reiterates Buy on Ideal Power (IPWR) Following ESNA Trade Show
-
Roth Capital Positive on Curis' (CRIS) Move into Immuno-Oncology Field; Reaffirms at 'Buy'
-
Roth Capital Cuts Price Target on Cempra (CEMP) as Solithromycin Misses High Expectations
-
Roth Capital Cits Price target After Synergy Resources (SYRG) Reports 6c EPS Miss
-
Roth Remains on Sidelines with PTC Therapeutics (PTCT) Until More Clarity is Observed; Affirms at 'Neutral'
-
Strongbridge Biopharma (SBBP) IPO Opens Up 30%
-
Strongbridge Biopharma plc Announces Pricing of Its Initial U.S. Public Offering
-
Strongbridge Biopharma plc Announces Pricing of Its Initial U.S. Public Offering
-
Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd
-
ROTH Capital Partners to Host Gene Therapy Corporate Access Day in New York on October 27th, 2015
-
Roth Capital Starts Horizon Global Corp. (HZN) at Buy
-
Roth Capital Cuts Price Target on Intel (INTC) Following 3Q Earnings Results
-
Take it One Month at a Time: LiquidSpace Launches Monthly Rentals, New Legal Framework
-
Hannon Armstrong (HASI) Prices 5M Common Stock Offering at $18/Share
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces the Pricing of its Public Offering of Common Stock
-
Hannon Armstrong (HASI) Commences 5M Share Common Stock Offering
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces Public Offering of Common Stock
-
Roth Capital Reiterates Buy on Unique Fabricating (UFAB) Following Announced New Program Order
-
Roth Capital Reiterates Buy on Zosano Pharma (ZSAN) Following Positive ZP-Glucagon Data
-
ROTH Capital Partners Releases its 2015-2016 Millennial Mom Survey
-
Roth Capital Reiterates Buy on uniQure (QURE) Ahead of Analyst/R&D Day
-
Roth Capital Assumes NVIDIA (NVDA) at Neutral
-
Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock

